Medications like Semaglutide (Ozempic, Wegovy) are gaining huge attention not only for diabetes but also for weight loss and cardiovascular protection. Recent trials (like SELECT) have shown reduced major cardiovascular events in non-diabetic obese patients, opening up new avenues for chronic disease prevention.
Should anti-obesity drugs be prioritize like other chronic disease treatments?
Ethical concerns of off-label use and cosmetic weight loss.?
3 Likes
India is also catching up with obesity. The paradox of India is here to see: Many areas in India are less of resources that we see malnutrition. While cities and urban areas are seeing rise of obesity.
Not a coincidence, thus, Novo Nordisk company is all set to launch its anti-diabetes and weight-loss drug Semaglutide (Wegovy) in India.
3 Likes